PHIA Koninklijke Philips N.V.

Philips becomes first medical device manufacturer granted new Underwriters Laboratories product cybersecurity testing firm registration

Philips becomes first medical device manufacturer granted new Underwriters Laboratories product cybersecurity testing firm registration

March 12, 2020

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company was named the first medical device manufacturer to receive a new (UL) product cybersecurity testing certification. Underwriters Laboratories (UL) is an independent global safety certification and testing company with locations worldwide.

The UL IEC 62304 certification was designed by Underwriters Laboratories to provide an overall framework to evaluate the robustness and maturity of a medical device manufacturer’s cybersecurity controls and capabilities for product development.

In support of the successful Philips firm registration for the security option of IEC 62304, UL performed a comprehensive audit of the Philips Security Center of Excellence. The Center was launched in 2015 to develop cyber-resilient products and services through security-by-design, risk assessment, vulnerability and penetration assessment, specialized trainings, and incident response.

The audit reviewed and verified core Philips product security processes, including security risk management and risk control measures, software security verification planning, change management and continuous improvement, and the Center’s laboratory quality management system.

The UL certification combines cybersecurity testing elements of the established UL 2900-2-1 standard for Software Cybersecurity for Network-Connectable Products, which focuses on the demanding requirements of healthcare and wellness systems, as well as security principles from international standards (ISO 13485 and ISO 14971).

“To receive this certification from Underwriters Laboratories, a long-established global leader in standards creation and safety testing, is a strong validation of our program and an opportunity to advance healthcare and personal health product security even further,” said Michael McNeil, Global Product Security & Services Officer, Philips.

“We’ve spent years building a successful and effective end-to-end Security by Design program, embedding security principles and best practices throughout a product’s life cycle,” McNeil added. “At Philips, we understand that our customers have high and growing expectations for the security of the solutions that they rely on. In addition, global regulatory authorities have also increased the scope and scale of product cybersecurity compliance requirements to help protect patients and consumers. We look forward to continuing to meet these critical commitments.”

For further information, please contact:

Mario Fante

Philips Global Press Office

Tel: =9226

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at . 

Attachments

EN
12/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips launches RADIQAL study to generate real-world evidence for new...

Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the USPrimary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the (R...

 PRESS RELEASE

Philips launches real-time 3D intracardiac imaging in Europe, expandin...

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D images in real timeCatheter offers enhanced procedural guidance without the need for general anesthesia, supporting more efficient and patient-friendly care for structural heart disease Amsterdam, the Netherlands – (NYSE: PHG...

 PRESS RELEASE

Philips successfully prices offering of Notes for EUR 1 billion to be ...

Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects May 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any ...

 PRESS RELEASE

Philips Future Health Index 2025: AI poised to transform global health...

Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now May 15, 2025AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, , highlighting the growing strain on global healthcare systems. The FHI 2025 Report, the largest global survey of its kind analyzing key concerns of healthcare professionals and patients, indicates AI holds promise for transforming care delivery. H...

Koninklijke Philips N.V.: 1 director

A director at Koninklijke Philips N.V. bought 8,176 shares at 24.410USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch